UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 Or 15(d) of the
Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): June 26, 2017
OXIS INTERNATIONAL,
INC.
(Exact name of
Registrant as specified in its charter)
|
Delaware
(State or other
Jurisdiction of
Incorporation or organization)
|
000-08092
(Commission File
Number)
|
94-1620407
(IRS Employer I.D.
No.)
|
100
South Ashley Drive, Suite
600
Tampa,
FL 33602
Phone: (800) 304-9888
(Address, including
zip code, and telephone number, including area code,
of
registrant's
principal executive offices)
N/A
(Former name,
former address and former fiscal year, if changed since last
report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting material
pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l
4a- l 2)
☐ Pre-commencement
communications pursuant to Rule l 4d-2(b) under the Exchange Act
(17 CFR 240. l 4d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240. l 3e-4(c))
Item 7.01 Regulation FD Disclosure.
On June 26, 2017, Oxis International, Inc. (the
“Company”) issued a press release announcing that the
Company agrees to acquire Georgetown Translational Pharmaceuticals,
Inc. and hire a new Chief Executive Officer and Chief Medical
Officer. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by
reference.
The information contained in this Item 7.01, and in Exhibit 99.1,
referenced herein is being furnished and shall not be deemed
"filed" for the purposes of Section 18 of the Securities Exchange
Act or incorporated by reference in any filing under the Securities
Act, unless the Company expressly so incorporates such information
by reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits:
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Press Release
issued by the Company on June 26, 2017.
|
SIGNATURE
PAGE
Pursuant to the
requirement of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Oxis
International, Inc.
|
|
|
|
|
|
|
|
|
Dated: June 26,
2017
|
|
By:
|
/s/ Steven
Weldon
|
|
|
|
|
|
Steven
Weldon
|
|
|
|
|
|
Chief Financial
Officer
|
|